Voltammetric behavior of antileukemia drug glivec. Part I - Electrochemical study of Glivec

被引:20
作者
Diculescu, Victor Constantin
Vivan, Marilene
Brett, Ana Maria Oliveira [1 ]
机构
[1] Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal
[2] Hosp Univ Coimbra, P-3000 Coimbra, Portugal
关键词
glivec; chronic myelogenous leukemia (CML); electrochemistry; voltammetry; adsorption;
D O I
10.1002/elan.200603591
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The electrochemical behavior of the antileukemia drug glivec was investigated at a glassy carbon electrode (GCE). The oxidation is a complex, pH-dependent, irreversible electrode process involving the transfer of 2 electrons and 2 protons and the formation of an electroactive product, P-glivec, which strongly adsorbs on the GCE surface and undergoes reversible oxidation. The adsorption of P-glivec at the GCE surface yields a compact monolayer that inhibits further oxidation of glivec. The electrochemical reduction is a simple pH dependent irreversible process involving the transfer of 2 electrons and 2 protons and occurs with the formation of a nonelectroactive product. The diffusion coefficient of glivec was calculated to be D-O = 7.35 x 10(-6) cm(2) s(-1) in pH 4.5 0.1 M acetate buffer.
引用
收藏
页码:1800 / 1807
页数:8
相关论文
共 28 条
  • [1] High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry
    Bakhtiar, R
    Lohne, J
    Ramos, L
    Khemani, L
    Hayes, M
    Tse, F
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02): : 325 - 340
  • [2] Quantification of the anti-leukemia drug ST1571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry
    Bakhtiar, R
    Khemani, L
    Hayes, M
    Bedman, T
    Tse, F
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) : 1183 - 1194
  • [3] Tyrosine kinase receptors as attractive targets of cancer therapy
    Bennasroune, A
    Gardin, A
    Aunis, D
    Crémel, G
    Hubert, P
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (01) : 23 - 38
  • [4] BRETT AMO, 2003, ELECTROANAL, V15, P1
  • [5] Brett CMA, 1993, Electrochemistry: Principles, Methods, and Applications
  • [6] Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes
    Czechowska, A
    Poplawski, T
    Drzewoski, J
    Blasiak, J
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2005, 152 (2-3) : 139 - 150
  • [7] DICULESCU VC, 2006, IN PRESS BIOELECTROC
  • [8] Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?
    Drummond, MW
    Holyoake, TL
    [J]. BLOOD REVIEWS, 2001, 15 (02) : 85 - 95
  • [9] Protein tyrosine kinase inhibitors: new treatment modalities?
    Fabbro, D
    Parkinson, D
    Matter, A
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) : 374 - 381
  • [10] Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine
    Flores, JR
    Berzas, J
    Castañeda, G
    Rodríguez, N
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 794 (02): : 381 - 388